Treatment of cutaneous T-cell lymphoma with retinoids
Authors:
- 1 September 2006
- journal article
- review article
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 19 (5) , 264-271
Abstract
Retinoids are biologic regulators of differentiation, proliferation, apoptosis, and immune response. Retinoids (all-trans retinoic acid, 13-cis-retinoic acid, and the synthetic analogs isotretinoin, etretinate, and acitretin) have been used for years as monotherapy and/or in combination for treatment of cutaneous T-cell lymphomas (CTCL). Orally administered bexarotene, the first synthetic highly selective retinoid X receptor retinoid to be approved by the Food and Drug Administration for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL. The topical gel formulation was also effective for early cutaneous manifestations of CTCL or as an adjunct to systemic or phototherapy. Use of retinoids in future long-term clinical trials and their eventual application in CTCL regiments will require strategies to decrease the side effects of existing retinoids, identify novel receptor subtype-selective retinoids with better therapeutic index, and explore biologically based synergistic combination therapies with other active agents.Keywords
This publication has 58 references indexed in Scilit:
- Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: A case seriesJournal of the American Academy of Dermatology, 2004
- Comparison of selective retinoic acid receptor– and retinoic X receptor–mediated efficacy, tolerance, and survival in cutaneous t-cell lymphomaJournal of the American Academy of Dermatology, 2004
- Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapyJournal of the American Academy of Dermatology, 2004
- Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanismsJournal of the American Academy of Dermatology, 2004
- Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trialJournal of the American Academy of Dermatology, 2003
- Combined modality therapy for cutaneous T-cell lymphomaJournal of the American Academy of Dermatology, 1996
- A retinoic acid receptor α antagonist counteracts retinoid teratogenicity in vitro and reduced incidence and/or severity of malformations in vivoToxicology Letters, 1994
- Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)Journal of the American Academy of Dermatology, 1992
- Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoidsJournal of the American Academy of Dermatology, 1991
- Treatment of cutaneous T-cell lymphoma with the arotinoid Ro 13-6298Journal of the American Academy of Dermatology, 1987